Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
Refractory (planetary science)
Cutaneous T-cell lymphoma
T-Cell Lymphoma
DOI:
10.1200/jco.2000.18.13.2603
Publication Date:
2017-02-24T09:08:21Z
AUTHORS (11)
ABSTRACT
To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with low-toxicity profile activity in several solid tumors, patients relapsed or refractory cutaneous T-cell lymphomas.Between May 1997 February 1999, 44 previously treated mycosis fungoides (MF; n = 30) peripheral lymphoma unspecified (PTCLU) exclusive skin involvement (n 14) were enrolled onto two-institution, phase II trial gemcitabine. This drug was given on days 1, 8, 15 28-day schedule at dose 1,200 mg/m(2) intravenously over 30 minutes for total three courses.Of patients, five (11. 5%) achieved complete responses (CRs), 26 (59%) partial (PRs), remaining 13 showed no benefit from treatment. Two CRs histologically confirmed. The CR PR rates same MF those PTCLU, respectively. No difference terms overall response rate observed between patients. median durations months (range, 6 to 22 months) 10 2 months), Treatment well tolerated; hematologic mild, nausea/vomiting organ recorded.The results present study show gemcitabine as single agent pretreated lymphoma. Further studies that use alone combination other drugs earlier stages disease are needed.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (187)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....